Literature DB >> 15262128

Loss of heterozygosity analysis in uterine cervical adenocarcinoma.

Kentaro Miyai1, Yoshiaki Furugen, Toshiharu Matsumoto, Keiichi Iwabuchi, Sachiko Hirose, Katsuyuki Kinoshita, Hiroaki Fujii.   

Abstract

OBJECTIVE: Uterine cervical adenocarcinoma (CAC) is a rare form of cervical cancer, constituting only 5-8% of all cervical epithelial malignancies. Loss of heterozygosity (LOH) analysis of CAC was undertaken to identify alterations of chromosomal loci that may play important roles in the development of this tumor type.
METHODS: We analyzed loss of heterozygosity (LOH) using a total of 50 markers on 20 chromosomal arms in 37 cases of microdissected CAC DNA.
RESULTS: LOH of >40% was observed on 2p (50%), 3p (45%), 9p (45%), 11q (46%), 17p (57%), 17q (44%), 18q (57%), and 19p (44%). LOH of 30-40% was observed on 6p (38%), 6q (40%), and 10q (31%). Overall, mean LOH was 34% and fractional allelic loss (FAL) was 0.34. High-level and low-level microsatellite instability (MSI) was shown in four cases (11%) and six cases (16%), respectively. Frequency of LOH on10q was significantly higher in endometrioid-type than endocervical-type adenocarcinoma (71% versus 20%; P < 0.05). Conversely, 6q LOH was higher in endocervical type than endometrioid type (0% versus 60%; P < 0.05). 19p13.3 has been reported to be frequently deleted in adenoma malignum, a histological subtype of CAC. To define the critical regions of LOH in CAC in general, we further performed deletion mapping of 19p using 13 markers. Unlike adenoma malignum, multiple regions on 19p appeared to be important loci of LOH for CAC.
CONCLUSION: CACs develop with frequent LOH of multiple chromosomal arms, which may be related to its aggressive clinical behavior and poor prognosis. LOH of 10q may be unique to endometrioid-type CAC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15262128     DOI: 10.1016/j.ygyno.2004.04.013

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.

Authors:  Yuefang Wang; Aurora O'Brate; Wei Zhou; Paraskevi Giannakakou
Journal:  Cell Cycle       Date:  2005-12-18       Impact factor: 4.534

2.  Clinical and microdissection genotyping analyses of the effect of intra-arterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma.

Authors:  David T Tse
Journal:  Trans Am Ophthalmol Soc       Date:  2005

3.  Allelic loss of 10q23.3, the PTEN gene locus in cervical carcinoma from Northern Indian population.

Authors:  M Moshahid Alam Rizvi; M Shabbir Alam; Syed Jafar Mehdi; Asgar Ali; Swaraj Batra
Journal:  Pathol Oncol Res       Date:  2011-09-08       Impact factor: 3.201

4.  RanBP3 enhances nuclear export of active (beta)-catenin independently of CRM1.

Authors:  Jolita Hendriksen; Francois Fagotto; Hella van der Velde; Martijn van Schie; Jasprien Noordermeer; Maarten Fornerod
Journal:  J Cell Biol       Date:  2005-11-28       Impact factor: 10.539

5.  A Comprehensive Review of Dysregulated miRNAs Involved in Cervical Cancer.

Authors:  Garima Sharma; Pradeep Dua; Subhash Mohan Agarwal
Journal:  Curr Genomics       Date:  2014-08       Impact factor: 2.236

6.  Clinical significance of the reduced expression of G protein gamma 7 (GNG7) in oesophageal cancer.

Authors:  M Ohta; K Mimori; Y Fukuyoshi; Y Kita; K Motoyama; K Yamashita; H Ishii; H Inoue; M Mori
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

7.  An Optimization-Driven Analysis Pipeline to Uncover Biomarkers and Signaling Paths: Cervix Cancer.

Authors:  Enery Lorenzo; Katia Camacho-Caceres; Alexander J Ropelewski; Juan Rosas; Michael Ortiz-Mojer; Lynn Perez-Marty; Juan Irizarry; Valerie Gonzalez; Jesús A Rodríguez; Mauricio Cabrera-Rios; Clara Isaza
Journal:  Microarrays (Basel)       Date:  2015-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.